BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives

Based on a series of phenylaminopyrimidinebased (PAP) derivatives that can inhibit BCR-ABL tyrosine kinase, a seven-point pharmacophore model was developed using Phase software. A statistically significant 3D-QSAR model was also yielded based on this pharmacophore model.